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Abstract 
Review on Retinoblastoma, with data on clinics, and 
the gene involved. 
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Identity 
Inheritance 
Predisposition to retinoblastoma is transmitted as an 
autosomal dominant trait trait with incomplete 
penetrance (Vogel F, 1979; Eloy P et al., 2016; 
Imperatore V et al., 2018);; it is caused by mutations 
in the RB1 gene; there is also a non-hereditary form 
of retinoblastoma (mostly in children with isolated 
unilateral retinoblastoma) that is caused by RB1-
mutations confined to somatic cells 
Clinics 
Retinoblastoma (RB) is the most common 
intraocular tumor in children, affecting about 1 in 
15,000 to 20,000 live births (Broaddus E et al., 
2009). It is caused by biallelic inactivation of RB1 
gene located at 13q14.2 (Knudson AG Jr, 1971; 
Friend SH et al., 1986).  
Figure 1.  In the non-hereditary form of retinoblastoma, the 
two RB1 mutations occur in somatic retinal cells. Only one 
eye is affected. Hereditary retinoblastoma arises when the 
first mutation is inherited via germinal cells. Tumor foci are 
initiated by the second mutation in somatic retinal cells. 
Many children with hereditable RB have new germinal 
mutations, and both parents are normal. Tumors may be 
unilateral or bilateral. 
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The most frequent form is the non hereditary one 
(60%), with both inactivating events occurring in 
retinal cells. In this form, the tumor is unilateral with 
onset after the first year of life in the majority of 
cases.  
The hereditary form (40%) is due to a RB1 germline 
predisposing mutation and subsequent somatic 
inactivation of the other allele. This form is 
generally multifocal and/or bilateral with an 
anticipation of the mean age of diagnosis (within the 
first year of life). Hereditary RB is transmitted 
according to an autosomal dominant pattern with 
incomplete penetrance, generally reported as equal 
to 90%. A significant fraction of mutation carriers 
remain unaffected or develop only benign lesions 
called retinomas (Harbour JW, 2001).  
Phenotype and clinics 
 Retinoblastoma in early childhood: white pupillary 
reflexes (leukocoria) in one or both eyes or 
strabismus usually are the first signs indicating this 
malignant eye tumour; other signs include glaucoma, 
inflammation and poor visual tracking (Abramson 
DH et al., 1998); in most children with the hereditary 
retinoblastoma, both eyes are affected by multiple 
tumour foci (bilateral multifocal retinoblastoma) 
Adults (most often relatives of patients with 
retinoblastoma) may show retinal scars indicating 
indicative of a benign lesion called (non-progressive 
tumours). 
 In addition to retinoblastoma, children with 
cytogenetic deletions involving 13q14 may show 
developmental delay and dysmorphic signs.  
Differential_diagnosis  
 Coats' disease 
 Persistent hyperplastic primary vitreous (PHPV) 
 Ocular toxocariasis 
 Other retinal tumors such as astrocytic hamartoma 
or medulloepithelioma 
 Hereditary disorders including tuberous sclerosis 
complex, Norrie disease, incontinentia 
pigmenti, familial exudative vitreoretinopathy, and 
von Hippel-Lindau syndrome 
 
Figure 2.  Ophtalmoscopic evaluation of 15X15 mm 
macular retinoblastoma (stage B). 
 
Figure 3.  Ophthalmoscopic examination of cystic retinoma 
on the right fundus oculi overwhelming the optic nerve 
head. 
Neoplastic risk 
Early childhood: formation of retinoblastomas  
Adolescence and adulthood: tumors outside the eye 
(second primary neoplasms): osteosarcoma, 
melanoma, brain tumours (pinealoma in particular 
some patients also show multiple benign tumours of 
adipose tissue (lipoma). 
Treatment 
Tumor stage, localization/size of the tumor, number 
of foci, presence of vitreous seeding and the age of 
the child can influence the treatment of RB.  
On the basis of these factors, therapeutic approaches 
can include focal cryotherapy, laser surgery, 
radiotherapy or chemotherapy.  
More recently, intra-arterial selective infusion of 
chemotherapy in the ophthalmic artery has been 
introduced (Peterson EC et al., 2011; Venturi C et 
al., 2013).  
However, enucleation (removal of the entire eye) is 
still the standard treatment for advanced intraocular 
RB, since it is effective in preventing progression to 
clinical metastatic disease in 95% of cases (Balmer 
A et al., 2006).  
Surveillance: following the diagnosis of 
retinoblastoma, repeated examinations under general 
anesthesia are required for early diagnosis of new 
tumour foci; up to now, no screening for second 
primary neoplasms. 
Prognosis 
Most often, treatment of retinoblastoma is very 
effective and, therefore, death from retinoblastoma 
is rare; however, life span in patients that develop 
second primary neoplasms is reduced (cumulative 
mortality at age 40: 6.4% in bilateral patients without 















Large-sized molecular deletions including RB1 have 
been found in 10% of cases  causing a contiguous 
gene deletion syndrome characterized by 
retinoblastoma, developmental abnormalities and 
peculiar facial dysmorphisms such as cranial 
anomalies, frontal bossing, deeply grooved and long 
philtrum, depressed and broad nasal bridge, bulbous 
tip of the nose, thin upper lip, broad cheeks, and large 
ears and lobules (Kloss et al., 1991; Bojinova RI et 
al., 2001; Lohmann and Gallie 2004; Albrecht P et 
al., 2005; Caselli R et al., 2007). Few cases of 
complex translocations resulting in retinoblastoma 
are reported, and chromosomes involved of balanced 
reciprocal translocations with 13q14 include 1, 2, 18, 
20, and X (Cross HE et al., 1977; Kajii T et al., 1985; 
Keith CG et al., 1985; Blanquet V et al., 1987; 
Trivino E et al., 1997; Laquis SJ et al., 2002; Dries 
D et al., 2003; Huddleston S et al., 2013). 









RB1 at 13q14 in normal cells: PAC 825K21 - 
Courtesy Mariano Rocchi 
Description 
180 kb genomic DNA containing 27 exons 
Transcription 
4.7 kb mRNA with 2.7 kb open reading frame 
Protein 
Description 
928 amino acids nuclear phosphoprotein. 
Expression 




Involved in cell cycle regulation, heterochromatin 
formation, maintenance of genome stability, 
regulation of cell differentiation and apoptosis 
(Dimaras H et al., 2015; Dyson NJ et al., 2016). 
 
 
Figure 4.  Schematic representation of the pRB protein with the sixteen recurrent mutations. RBN, amino-terminal domain; 














More than 1,700 different mutations, ranging from 
single nucleotide changes to large deletions, have 
been listed in the RB1 Gene Mutation Database 
(http://rb1-lovd.d-lohmann.de). A large fraction 
(~40%) of mutations are recurrent and consist in 
sixteen hot spots, including twelve nonsense, one 
missense and three splicing mutations (Valverde JR 
et al., 2005). Remaining mutations are scattered 
along the 27 exons, the promoter and intronic 
regions (splice site and deep intronic mutations). 
Complete inactivation of the protein is the result of 
the majority of RB1 mutations (complete loss of 
function, amorphic mutations). These mutations, 
mostly represented by nonsense and frameshift 
changes resulting in premature termination codons 
(PTC), are generally associated with full penetrance 
(Valverde JR et al., 2005). RB1 amorphic mutations 
can be associated to reduced penetrance in 
association with somatic mosaicism (Imperatore V et 
al., 2018). Hypomorphic mutations partially 
inactivating protein function or reducing gene 
expression combined with a parent-of-origin effect 
can also be associated to incomplete penetrance or 
variable expressivity (Kanber D et al., 2009; Eloy P 
et al., 2016; Imperatore V et al., 2018). Another 
important class of RB1 oncogenic events is 
represented by large rearrangements (~15%; Taylor 
M et al., 2007). They can include only the RB1 gene 
(entire or a portion) or be a part of a larger 
contiguous deletion involving other genes. Whole 
gene deletions are associated to the development of 
fewer tumors (Albrecht P, et al. 2005; Taylor M et 
al., 2007).  A minimal genomic region associated 
with low penetrance has been defined and MED4 has 
been identified as a gene fundamental for the 
survival of RB1-/- tumor cells (Dehainault C et al., 
2014). 
Somatic 
In the majority of retinoblastoma tissues, the 
mutations that result in biallelic inactivation of the 
RB1 gene are accompanied by loss of constitutional 
heterozygosity (LOH), originating from deletions 
and several chromosomal mechanisms such as 
mitotic recombination and nondisjunction (Cavenee 
WK et al., 1983; Zhu X et al., 1992; Hagstrom SA 
and Dryja TP, 1999; Lohmann DR et al., 1997). RB1 
promoter hypermethylation is observed in about 
13% of retinoblastomas (Greger V et al., 1994; 
Ohtani-Fujita N et al., 1997; Klutz M et al., 1999). 
Epigenetics 
 In 2009 a 1.2 kb CpG island inside intron 2  (CpG 
85) of RB1 was found to show parent-of-origin 
specific methylation (Kanber D et al., 2009). It is 
methylated on the maternal chromosome 13 and acts 
as a weak promoter for an alternative RB1 transcript 
on the paternal chromosome 13. Paternal mRNA 
levels are reduced as the result of transcriptional 
interference of the regular promoter resulting in a ~3 
fold excess of the RB1 maternal canonical transcript.  
As a consequence, RB1 maternally inherited 
pathogenic variants with hypomorphic effect can 
retain sufficient suppressor activity to prevent tumor 
development. 
 In retinoblastoma tissues methylation of a CpG 
island (CpG106) encompassing the promoter region 
of RB1 is a quite frequent mechanism inactivating 
one copy of the gene (Greger et al., 1994). The same 
predisposing event in patients' non tumor cells has 
been rarely described (Jones et al., 1997; Gelli E et 
al. 2019). 
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